FN1 and glioblastoma: As an additional assessment of clinical significance, the applicability of EDB-FN as a prognostic biomarker in brain tumors, especially in the GBM group with the highest EDB-FN expression levels ('grade IV'), was analyzed using quantile normalization values from the datasets.